3,100
Participants
Start Date
December 23, 2019
Primary Completion Date
April 1, 2026
Study Completion Date
April 1, 2027
(Intervention) Recommending HPV vaccine for patients 9-10 years of age
Practices are randomized to receive training on how to recommend HPV vaccine, including both standardized communication strategies and strategies for switching from 11-12 years to 9-10 years including: challenges with 11-12 strategy, long-term immunity, success of other practices and tips to help standardize to age 9-10. Trainings will be a combination of online and in-person or virtual. Annual trainings will be offered and providers will receive Maintenance of Certification credits (MOC) for participating. Providers will routinely recommend HPV starting at age 9 for all patients -- which is already approved for this vaccine but is not routinely recommended at age 9 years.
(Control) Recommending HPV vaccine for patients 11-12 years of age
Control practices will receive a training on standardized communication for HPV vaccine including: using strong recommendations, using presumptive recommendation, providing specific phrases to use with parents, answering common questions and, HPV vaccine as a cancer prevention. Annual trainings will be offered and providers will receive professional development credit (MOC).
RECRUITING
University of Colorado, Aurora
RECRUITING
University of California at Los Angeles, Los Angeles
National Institutes of Health (NIH)
NIH
National Cancer Institute (NCI)
NIH
University of Colorado, Denver
OTHER